Table 1 Subject demographics.
Characteristic | Patient subjects n = 65 | Control subjects n = 28 | p-value |
|---|---|---|---|
Age, Years (mean ± SD) | 48 ± 11 | 40 ± 10 | 0.47 |
Sex (female) | 34 (61) | 10 (66) | 0.91 |
BMI, kg.m−2 (mean ± SD) | 30 ± 7 | 27 ± 5 | 0.38 |
Race (n, %) | |||
African–American | 59 (90) | 21 (75) | 0.52 |
White | 3 (4) | 7(25) | 0.31 |
Other | 3 (4) | 0 | 0.08 |
Smoker (PY)(mean ± SD) | 5 ± 8 | 0 | 0.00 |
Organ involvements (n, %) | |||
Pulmonary Involvement | 64 (98) | NA | – |
Extra Pulmonary Involvement | 48 (73) | NA | – |
Skin | 31 (47) | NA | – |
Eye | 24 (43) | NA | – |
Heart | 5 (9) | NA | – |
CNSa | 4 (7) | NA | – |
Other | 22 (33) | NA | – |
Initial chest radiograph stages (n, %) | |||
Stage 0 | 2 (3) | NA | – |
Stage 1 | 9 (16) | NA | – |
Stage 2 | 31 (56) | NA | – |
Stage 3 | 6 (10) | NA | – |
Stage 4 | 4 (7) | NA | – |
Initial PFTb, mean (rangec) | |||
FVCd (% predicted) | 86 (44–123) | NA | – |
FEV1e (% predicted) | 81 (27–121) | NA | – |
FEV1/FVC (% predicted) | 75 (36–98) | NA | – |
TLCf (% predicted) | 80 (37–110) | NA | – |
DLCOg (% predicted) | 65 (27–120) | NA | – |
